UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2020

Commission File Number: 001-39173

I-MAB

Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District
Shanghai, 201210
People's Republic of China
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

I-MAB

By : /s/ Jielun Zhu
Name : Jielun Zhu
Title : Director and Chief Financial Officer

Date: April 8, 2020

Exhibit Index

Exhibit 99.1—Press Release


Exhibit 99.1
I-MAB
BIOPHARMA
April 2020
I-MAB Presentation

Disclaimer

This presentation has been prepared by I-Mab (the "Company") solely for information purpose. By viewing or accessing the information contained in this material, you hereby acknowledge and agree that no representations, warranties, or undertakings, express or implied, are made by the Company or any of its directors, shareholders, employees, agents, affiliates, advisors, or representatives as to, and no reliance should be placed upon, the accuracy, fairness, completeness, or correctness of the information or opinions presented or contained in this presentation. None of the Company or any of its directors, shareholders, employees, agents, affiliates, advisors, or representatives accept any responsibility whatsoever (in negligence or otherwise) for any loss howsoever arising from any information presented or contained in this presentation or otherwise arising in connection with the presentation. The information presented or contained in this presentation is subject to change without notice and its accuracy is not guaranteed.

This presentation does not constitute an offer to sell or issue or an invitation or recommendation to purchase or subscribe for any securities of the Company for sale in the United States or anywhere else. No securities of the Company may be sold in the United States without registration with the United States Securities and Exchange Commission (the "SEC") or an exemption from such registration pursuant to the Securities Act of 1933, as amended (the "Securities Act") and the rules and regulations thereunder. No part of this presentation shall form the basis of or be relied upon in connection with any contract or investment decision in relation to any securities or otherwise. This presentation does not contain all relevant information relating to the Company or its securities, particularly with respect to the risks and special considerations involved with an investment in the securities of the Company. Nothing contained in this presentation shall be relied upon as a promise or representation as to the past or future performance of the Company. Past performance does not guarantee or predict future performance. You acknowledge that any assessment of the Company that may be made by you will be independent of this presentation and that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company.

Certain statements in this presentation, and other statements that the Company may make, are forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. These statements reflect the Company's intent, beliefs, or current expectations about the future. These statements can be recognized by the use of words such as "expects," "plans," "will," "estimates," "projects," "intends," "anticipates," "believes," "confident," or words of similar meaning. These forward-looking statements are not guarantees of future performance and are based on a number of assumptions about the Company's operations and other factors, many of which are beyond the Company's control, and accordingly, actual results may differ materially from these forward-looking statements. The Company or any of its affiliates, advisers, or representatives has no obligation and does not undertake to revise forward-looking statements to reflect future events or circumstances.

THE INFORMATION CONTAINED HEREIN IS HIGHLY CONFIDENTIAL AND IS BEING GIVEN SOLELY FOR YOUR INFORMATION AND ONLY FOR YOUR USE IN CONNECTION WITH THIS PRESENTATION. THE INFORMATION CONTAINED HEREIN MAY NOT BE COPIED, REPRODUCED, REDISTRIBUTED, OR OTHERWISE DISCLOSED, IN WHOLE OR IN PART, TO ANY OTHER PERSON IN ANY MANNER. Any forwarding, distribution, or reproduction of this presentation in whole or in part is unauthorized.

By viewing, accessing, or participating in this presentation, you hereby acknowledge and agree to keep the contents of this presentation and these materials confidential. You agree not to remove these materials, or any materials provided in connection herewith, from the conference room where such documents are provided. You agree further not to photograph, copy, or otherwise reproduce this presentation in any form or pass on this presentation to any other person for any purpose, during the presentation or while in the conference room. You must return this presentation and all other materials provided in connection herewith to the Company upon completion of the presentation. By viewing, accessing, or participating in this presentation, you agree to be bound by the foregoing limitations. Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

Key Investment Highlights

I-Mab Transitioning from I-Mab 1.0 to I-Mab 2.0

Innovative and Risk-Balanced Pipeline: *Two Portfolios*

China **China Strategy – *Fast-to-Market***

5 *clinical assets*

BLA 2021 onwards

Global **In-licensing** China

Discovery | Pre-Clinical | IND Enabling | Phase 1 / Phase 2 | Phase 3 | BLA | Marketing

China US **Global Partnership**

Global **Global Strategy – *Fast-to-PoC***

Internal R&D **12** *clinical & pre-clinical assets* **Clinical Validation**



Innovative Pipeline of Novel and Highly Differentiated Potential

	Drug Candidate (Licensor)	Indication/ Therapeutic Area	Commercial Rights	Preclinical	Phase 1	Phase 2	Phase 3	Expected NDA / BLA Filing
China Portfolio	**TJ202 (MorphoSys)** [1] *Differentiated CD38 antibody*	Multiple myeloma/ Autoimmune disease	Greater China				BLA 2021	2021-2024
	Eftansomatropin TJ101 (Genexine) [2] *Long-acting growth hormone*	Pediatric growth hormone deficiency	Greater China				BLA 2023	
	Olamkicept TJ301 (Ferring) *Soluble gp130 IL-6 inhibitor*	Ulcerative colitis/ Autoimmune disease	Greater China S. Korea					
	Enoblituzumab (MacroGenics) [3] *B7-H3 antibody*	Head and neck cancer/ Oncology	Greater China					
	Efineptakin TJ107 (Genexine) *Novel long-acting IL-7*	Oncology-related lymphopenia	Greater China					
Global Portfolio	**TJM2** *GM-CSF antibody*	Autoimmune disease/Cytokine release syndrome	Global					2024-
	TJC4 *Differentiated CD47 antibody*	Multiple cancer indications	Global					
	TJD5 *Differentiated CD73 antibody*	Multiple cancer indications	Global					
	TJ210 (MorphoSys) *Differentiated C5aR antibody*	Oncology/ Autoimmune disease	Greater China Global shared					
	TJX7 *Novel CXCL13 antibody*	Autoimmune disease	Global					
	Bi-specific antibody panel [4] *including five PD-L1-based bi-specifics, TJ-C4GM and TJ-CLDN4B*	Multiple cancer indications	Global Some shared					

Notes

1. TJ202 has two ongoing registrational trials, a monotherapy trial and a combination therapy trial in relapsed or refractory multiple myeloma in Greater China, and we will soon initiate a Phase 1b trial in systemic lupus erythematosus ("SLE") in the first half of 2020
2. For TJ101, we expect to submit an IND for a Phase 3 registrational trial in China by early 2020
3. For enoblituzumab, we expect to initiate either a registrational trial or a Phase 2 trial (pending NMPA's regulatory approval) by the end of 2020
4. Our bi-specific antibody panel consists of (i) five PD-L1-based bi-specific antibodies, including TJ-L1I7 (PD-L1 and IL-7 cytokine fusion), TJ-L1C4 (PD-L1 and CD47), TJ-L1D5 (PD-L1 and CD73), TJ-L1H3 (PD-L1 and B7-H3), and TJ-L14B (PD-L1 and 4-1BB), (ii) TJ-C4GM (anti-CD47 and GM-CSF), and (iii) TJ CLDN4B (Claudin 18.2 and 4-1BB)

The Emerging Value Drivers: *Critical Product Differentiation*

Clinical Assets	Key Differentiation	Clinical Development Plan
TJ202 *Differentiated CD38 mAb*	**Short infusion time** (0.5 – 2 hrs) and **lower IRR** (7%) Combination with **Lenalidomide** as 2nd line therapy	▪ Two on-going registrational trials in **MM** to target **BLA in 2021** ▪ Ph 1b trial in **SLE** in 2020
TJ101 *Differentiated long-acting hGH*	Convenient **weekly dosing** vs. daily injections **Better safety profile** (HyFc) vs. pegylated hGH	▪ Planned IND for **Ph 3 in PGHD** in mid 2020 ▪ **BLA** expected in 2023
TJC4 *Differentiated CD47 mAb*	**Strong anti-tumor activity** **Minimal binding to RBC** due to a unique epitope **No severe anemia** (GLP tox up to 100 mg/kg)	**US trial on-going in solid tumor/lymphoma:** ▪ Safety advantage (dose-escalation, 1-30 mg/kg) ▪ Combination with PD-1/CD20 **China trial starting:** AML/MDS
TJD5 *Differentiated CD73 mAb*	Intra-dimerization mechanism: **no "hook effect"** MoA with **broader tumor indications**	▪ **US trial on-going:** Phase 1 combo with PD-L1 ▪ **China trial starting:** Phase 1 combo with PD-1

TJC4: Minimal Binding to Red Blood Cells by Design

RBC Agglutination





RBC Binding





TJC4: Safety Advantage Demonstrated in Cyno Monkeys

Pilot-single dose



Pilot-repeat dose



4-wk GLP-Tox

Male



Female



TJC4: Comparable Anti-Tumor Activity in Animal Models



Treatment of TJC4 eradicated the engrafted tumor cells, comparable to 5F9 and 2A1 reference mAbs.

TJC4: Parallel Clinical Development in US and China

US development goals:

- **Evaluation of the safety differentiation** in solid tumor/lymphoma to complete by Q3
- **Combination therapy** with PD-1 inhibitor pembrolizumab (KEYTRUDA®) and Rituximab (RITUXAN®) to evaluate safety and early efficacy signal in solid tumors and lymphoma

China development goal:

- **AML/MDS.** Developing goal for registration in China for the indications



TJC4 – *A Differentiated CD47 Antibody in Clinical Development*



TJD5: A Potential Highly Differentiated CD73 Antibody

Highlights

TJD5

Novel Mechanism Targeting Tumor Microenvironment	Differentiated CD73 Antibody Drug Candidate



TJD5's inhibition of CD73 by intra-dimerization

Advantages

No "hook effect" through intra-dimerization mechanism

A substrate non-competitive pathway

Summary of Pre-clinical Results

Pre-clinical Data

Differentiated Property without the Hook Effect



Potentiation of Antitumor Activities in combination with PD-L1 Antibody



Clinical Development Plan

Targeting multiple solid tumor types, with parallel development in the U.S. and China

Phase 1 clinical trial in patients with advanced solid tumors in partnership with TRACON Pharmaceuticals

- To evaluate safety & tolerability
- To explore PK/PD and potential efficacy of the combination therapy with atezolizumab

Phase 1/2 clinical trial in patients with advanced solid tumors including lung cancer, Obtained IND approval from the NMPA in September 2019

- To evaluate safety & tolerability
- To explore PK/PD and potential efficacy of the combination therapy with Toripalimab

TJ202: Potential Best-in-Class CD38 Antibody for Multiple Myeloma and Autoimmune Diseases

Highlights

TJ202

Differentiated CD38 mAb	First BLA Expected in 2021	Potentials in Autoimmune Diseases



TJ202 binds to CD38 overexpressed tumor cells, pathogenic CD38-positive B cells and plasma cells, killing its mediator by inducing antibody-dependent cytotoxicity (ADCC) and antibody-dependent phagocytosis (ADCP)

Target Indication

Multiple Myeloma (MM)

- Approximately 20,500 new cases of MM in 2018 in Greater China
- China MM biologics market size is estimated at US$ 0.8 billion in 2030
- Recently marketed daratumumab in China has a long infusion time of administration (up to 6 hours) and a high infusion reaction rate (IRR)

Systemic Lupus Erythematosus (SLE)

- Estimated prevalence of 1.04 million in 2018 in Greater China
- China SLE biologics market size is estimated at US$ 1.8 billion in 2030
- Belimumab is currently the world's only biologic approved to treat SLE
- Unmet medical need for an efficacious and safe treatment alternative

Advantages

Convenience and Safety

Shorter infusion time (0.5 – 2 Hours)

Lower infusion reaction rate (7%)

Expected Efficacy in Autoimmune Diseases

Targeting pathogenic CD38-positive B cells and plasma cells

Eftansomatropin TJ101: Potential Best-in-Class Long-Acting Growth Hormone for Growth Hormone Deficiency

Highlights

TJ101

Convenient Weekly or Bi-weekly Dosing with Safety Advantages

TJ101 is engineered using Genexine's proprietary hyFc technology



The clinical results from a Phase 2 trial in PGHD conducted in Europe indicated weekly or bi-weekly treatment with TJ101 produced similar efficacy compared to daily Genotropin administration

Target Indication

Pediatric Growth Hormone Deficiency (PGHD)

- PGHD affected approximately 3.4 million patients in 2018 in Greater China
- **Huge unmet medical need as** only 3.7% of all PGHD patients in China were receiving growth hormone replacement therapy in 2018
- China PGHD therapeutics market size is US$ 0.6 billion in 2018, and is estimated to increase to US$ 3.2 billion in 2030, a CAGR of 15.7%

Short-Acting (Daily Injection)	Long-Acting (Weekly/Bi-weekly Injection)
• Short-acting rhGH is the most commonly used treatment in China • Not convenient with poor patient compliance	• Jintrolong is currently the only approved long-acting pegylated rhGH in China • Potential safety concerns related to long-term use of pegylated drugs • TJ101 is the only Fc-based long-acting rhGH ready for a Phase 3 clinical trial in China

Clinical Development Plan

Currently in preparation for a Phase 3, randomized, active controlled, and multi-center study to demonstrate non-inferiority of weekly TJ101 compared to Jintropin, a daily rhGH marketed in China

IND submission expected in 2020

TJM2: Treatment for cytokine storm in severe COVID-19 infected patients

Scientific rationale



GM-CSF and IL-6 are two key factors instigating cytokine storm in COVID-19. Antibodies neutralizing GM-CSF or IL-6/IL-6R may be used to prevent or treat cytokine storm associated with COVID-19.

Advantages

- Specifically neutralizes GM-CSF which is key factor to induce cytokine storm in COVID-19
- Regulates the inflammatory cytokine network via the upstream intervention
- Targets myeloid lineage cells with no influence on lymphocytes to avoid the entire immune suppression
- Supported by preclinical research and safety profile of the phase 1 study

GM-CSF blockade reduced cytokines that were elevated in COVID-19 patients



- Cytokines in **red** are elevated in severe COVID-19 cases requiring ICU.

Clinical Development Plan

Targeting severe COVID-19 patients in the U.S.

I/E criteria:
- RT-PCR confirmed novel Coronavirus infection
- Imaging confirmed infection in both lungs
- Severe or critical novel Coronavirus pneumonia

Stratifications:
- Ventilation: yes/no
- Older than 60y: yes/no

Primary endpoints:
- Proportion of deterioration in clinical status from baseline (D14)

Secondary endpoints:
- SOFA score
- PaO2/FiO2
- Changes in serum cytokines
- All-cause mortality
- And etc.

Expected Major Catalysts in 2020

Category	2020		
Clinical Milestone	**TJC4 US** safety data readout	**TJC4 China** trial start in AML/MDS	**TJ202 China** SLE trial start
	TJD5 US safety data readout	**TJD5 China** trial start in solid tumor	**TJ101 China** Ph 3 IND submission
	TJM2 US and Korea IND for CRS	**TJM2 China** Ph 1b start in RA	**TJ301 China** Ph 2 topline data
	TJ210 US IND and Ph 1 trial start		**TJ107 China** Ph 2 trial start
	TJX7 US IND and Ph 1 trial start		
Corporate Milestone		Expansion of US R&D center	Manufacture facility in China
			Potential global or China partnerships

Senior Management with a Proven Track Record of Success

Zheru Zhang, Ph.D.

President

- 20+ years of experience in CMC and quality management in pharma industry in US, Korea and China
- Previously served management roles at BMS, J&J and Celltrion
- Led or participated in 20 biologics IND and six global BLA submissions
- Ph.D., University of Alberta
- M.S., Suzhou University

Jielun Zhu, MBA, CFA

CFO

- 10+ years in investment banking, 4 years experience in healthcare consulting
- Served as MD and Asia Head of Healthcare Investment Banking for Jefferies, and a core healthcare team member at DB and UBS AG
- M.B.A., Harvard Business School
- B.A., Wesleyan University

Joan Shen., M.D., Ph.D.

CEO and Director

- US licensed physician with 20+ years of clinical development experience and China
- Ex-China Clinical Head at Pfizer, Ex-CMO at Jiangsu Hengrui, Ex-China Development Head at J&J
- Ph.D., Postdoc, Indiana University School of Medicine
- M.S., West China University of Medical Sciences
- M.D., Southeast University Medical College

Dr. Jingwu Zang, M.D., Ph.D.

Founder, Honorary Chairman and Director

- M.D., Shanghai Jiaotong University
- Ph.D., University of Brussels
- Post-doc, Harvard Medical School
- Clinical residency, Baylor College of Medicine, US-licensed physician

Industry Experiences

- 12 years of pharma R&D executives
- Ex-CSO and President of Simcere Pharmaceuticals
- Corporate SVP, Head of GSK China R&D Center

Academic Achievements

- Professor at Baylor College of Medicine
- Professor & founding director in Chinese Academy of Science
- Published over 160 papers in scientific journals

Neil K. Warma, MBA

US General Manager

- Ex-President and Ex-CEO of Opexa Therapeutics (NASDAQ:OPXA), Ex-President and Ex-CEO of Viron Therapeutics, Founder and Ex-President of MedExact
- Ex-Head of International Pharma Policy & Advocacy at Novartis
- Board of Director of BioHouston
- B.Sc., University of Toronto
- M.B.A., Schulich School of Management at York University

Distinguished Scientific Advisory Board

Patricia LoRusso, D.O., M.A., Ph.D.

Academic Achievements
- Associate Director of Innovative Medicine and Director of Early Therapeutics Disease-Aligned Team at Yale Cancer Center

Industry Experience
- Member of the NCI Board of Scientific Council

R&D Highlights
- Dr. LoRusso heads the early clinical trials program at Yale Cancer Center and has been a Principal Investigator of the National Cancer Institute Phase 1/early phase clinical trials program grant in excess of 20 years

Eric K. Rowinsky, M.D.

Academic Achievements
- Adjunct Professor of Medicine at New York University School of Medicine

Industry Experience
- Advisor to C-Bridge Capital
- U.S. Chief Medical Officer for Everest Medicines, Inc.

R&D Highlights
- At ImClone Systems (now a wholly-owned subsidiary of Eli Lilly), Dr. Rowinsky and his team developed and registered cetuximab (Erbitux) and ramucirumab in five indications and two other monoclonal antibodies

Howard L. Weiner, M.D.

Academic Achievements
- Robert L. Kroc Professor of Neurology at the Harvard Medical School

Industry Experience
- Co-Director of the Ann Romney Center for Neurologic Diseases at Brigham & Women's Hospital in Boston

R&D Highlights
- Dr. Weiner pioneered immunotherapy in Multiple Sclerosis (MS) and has investigated immune mechanisms in nervous system diseases including MS, Alzheimer's disease, amyotrophic lateral sclerosis, stroke and brain tumors

Yi-Long Wu, M.D.

Academic Achievements
- Winner of Outstanding Science Achievement from IASLC (IASLC Paul A. Bunn, Jr. MD Scientific Award)

Industry Experience
- Tenured Professor of Guangdong General Hospital (GGH)

R&D Highlights
- Prof. Wu is a pioneer of lung cancer research in China, gaining tremendous recognition from peers all over the world. He has committed himself to battling thoracic oncology at the front line

Timothy A Yap, M.D, Ph.D.

Academic Achievements
- Associate Professor of Department for Investigational Cancer Therapeutics (Phase 1 Program) and the Department of Thoracic/Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center

Industry Experience
- Medical Director of the Institute for Applied Cancer Science
- Associate Director of Translational Research in the Institute for Personalized Cancer Therapy

R&D Highlights
- Dr. Yap's main research focuses on the first-in-human and combinatorial development of molecularly targeted agents and immunotherapies, their acceleration through clinical studies using novel predictive and pharmacodynamics biomarkers

Roy S. Herbst, M.D, Ph.D.

Academic Achievements
- Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology and the Chief of Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital

Industry Experience
- Associate Cancer Center Director for Translational Research, Yale Cancer Center in New Haven

R&D Highlights
- Dr. Herbst is best known for his work in developmental therapeutics and the personalized therapy of non-small cell lung cancer, in particular the process of linking genetic abnormalities of cancer cells to novel therapies

Dual Expertise in U.S. and China with Strategic Global Footprint of Partners

Notes
1. Headquarters of companies that partner with I-Mab.
2. In April 2017, our subsidiary I-Mab Shanghai entered into a technology transfer agreement (the "HDYM License") with Ningbo Hou De Yi Min Information Technology Co., Ltd. ("HDYM") and Hangzhou HealSun Biopharm Co., Ltd. ("HealSun"), which is a portfolio company of Lepu Biotech.
3. In March 2020, our subsidiary I-Mab Biopharma US Limited entered into a strategic alliance agreement with Kalbe Genexine Biologics, a joint venture between Kalbe Farma Tbk and Genexine, Inc.

Strategic Partnerships with Leading Global Companies

Multiple Collaborations Established with Quality Partners

	Product	Partner	Partner Market Cap	Ticker	Commercial Rights	Date
In-license	Olamkicept (IL-6 blocker)	FERRING PHARMACEUTICALS	Private	Private	Greater China, S. Korea	2016.11
	TJ202 (CD38) TJ210 (C5aR)	morphosys	US$ 3.4Bn	FRA: MOR, NASDAQ: MOR	Greater China Greater China, S. Korea	2017.11/ 2018.11
	TJ101 (Long-acting hGH) / Efineptakin TJ107	Genexine	US$ 1.1Bn	KOSDAQ: 095700	China Greater China	2015.10/ 2017.12
	Enoblituzumab (B7-H3 antibody)	MacroGenics	US$ 549.6Mn	NASDAQ: MGNX	Greater China	2019.07
Partnership	WuXiBody Platform Strategic Manufacturing Partner Investor	WuXi Biologics	US$ 12.9Bn	SEHK: 2269	Worldwide	2018.09/ 2019.04/ 2019.07
	Strategic Commercial Partner	KALBE	US$ 2.9Bn	IDX:KLBF	South East Asia, MENA	2020.03
Co-development	Tecentriq for combo with TJD5	Roche	US$ 247.0Bn	SWX: ROG	Global (excl China)	2019.03
	KEYTRUDA® (pembrolizumab) for combo with TJC4	MSD	US$ 216.8Bn	NYSE:MRK	Worldwide	2019.09
	Toripalimab (anti-PD-1 mAb) for combo with TJD5	拓臻生物 TopAlliance	US$ 2.8Bn	SEHK: 1877, NEEQ: 833330	China	2019.09
	TJD5 (CD73 antibody)	TRACON	US$ 9.0Mn	NASDAQ: TCON	North America	2018.11
Out-license	PD-L1 antibody	LEPU MEDICAL	US$ 6.9Bn	SZSE: 300003	Worldwide	2017.04
	Bispecific antibody	ablbio	US$ 734.9Mn	KOSDAQ: 298380	Ex- Greater China	2018.07
	TJ103 long-acting GLP-1	CSPC 石药集团	US$ 13.3Bn	SEHK: 1093	Greater China	2018.12

Strong Shareholder Base with Prominent Investors

Raised over US$500 Million in 3 Years with Leading Chinese and Global Healthcare and Biotech Investors

Raised Over US $500 Million with Leading Global Healthcare and Biotech Investors

Shareholder Breakdown (1)(3)



Note:
1. Based on common shares outstanding
2. Other IPO shareholders exclude: GIC, Genexine, Lake Bleu, C-Bridges
3. ESOP on fully diluted basis is 13.4% of shares outstanding

(2)

Fundraising History

Round	Amount ($USD)
Seed	$2.3M
Series A	$58M
Series B	$120M
Series C	$200M
Series C-1	$27M
IPO	$115M
TOTAL	**$522.3M**

Well Capitalized to Pursue Ongoing R&D Activities

Total Cash Position [1]



Historical Revenue

2019 R&D Expenses

2019 R&D expenses total RMB$840.4MM (US$120.7MM) which primarily consists of:

- CRO service fees
- In-licensed patent right fees, including US$15mil upfront payment to MacroGenics
- Employment benefit expenses, including upfront R&D staff salary and benefits payment
- Material cost for drug candidates

Note:
1. Total cash position include: cash and cash equivalent, restricted cash, and short-term investments. Restricted cash represents cash that cannot be withdrawn without the permission of third parties, and deposits held in a separate reserve account as security deposits under bank borrowing agreements

Financial Summary

Selected Financials	Full Year Ended	
(All amounts in RMB thousands, except for per share data)	December 31, 2018	December 31, 2019
Cash, Cash Equivalents, Restricted Cash and Short-Term Investments	1,680,931	1,225,283
Total Revenues (Licensing and Collaboration Revenue)	53,781	30,000
Total Expenses	(492,419)	(1,494,968)
Research & Development Expenses	(426,028)	(840,415)
Administrative Expenses	(66,391)	(654,553)
Net Loss	(402,833)	(1,451,950)
Net Loss Attributable to Ordinary Shareholders	(402,833)	(1,485,001)
Net Loss Per Share Attributable to Ordinary Shareholders (Basic and Diluted)	(61.7)	(201.2)
Non-GAAP Adjusted Net Loss	(399,313)	(936,747)
Non-GAAP Adjusted Net Loss Attributable to Ordinary Shareholders	(399,313)	(969,798)
Non-GAAP Adjusted Net Loss Per Share Attributable to Ordinary Shareholders (Basic and Diluted)	(61.2)	(131.4)